热烈祝贺小组王成博士、刘星辰硕士、陆德华硕士顺利毕业

三位同学经过努力取得了不俗的成绩

王成博士发表两篇JMC，一篇EJMC，还有一篇马上投稿。

Cheng Wang, Lailiang Qu, Shang Li, Fucheng Yin, Limei Ji, Wan Peng, Heng Luo, Dehua Lu, Xingchen Liu, Xinye Chen, Lingyi Kong*, and Xiaobing Wang*, Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA, Journal of Medicinal Chemistry, 2021, 64: 12630-12650. DOI: 10.1021/acs.jmedchem.1c00567. IF：7.446

Cheng Wang, Shang Li, Jinhua Zhao, Huali Yang, Fucheng Yin, Ming Ding, Jianguang Luo, Xiaobing Wang*, Lingyi Kong*.  Design and SAR of Withangulatin A Analogues that Act as Covalent TrxR Inhibitors through the Michael Addition Reaction Showing Potential in Cancer Treatment. Journal of Medicinal Chemistry, 2020, 63, 11195-11214, DOI: 10.1021/acs.jmedchem.0c01128。IF：7.446

Cheng Wang, Xinye Chen, Xingchen Liu, Dehua Lu, Shang Li, Lailiang Qu, Fucheng Yin, Heng Luo, Yonglei Zhang, Zhongwen Luo, Ningjie Cui, Lingyi Kong*, Xiaobing Wang*，Discovery of Precision Targeting EZH2 Degraders for Triple-Negative Breast Cancer, European Journal of Medicinal Chemistry, Available online 20 May 2022, 114462. DOI: 10.1016/j.ejmech.2022.114462  IF 6.514

刘星辰同学一篇JMC，一篇CJNM

Dehua Lu, Lailiang Qu, Cheng Wang, Heng Luo, Shang Li, Fucheng Yin, Xingchen Liu, Xinye Chen, Zhongwen Luo, Ningjie Cui, Wan Peng, Limei Ji, Lingyi Kong*, and  Xiaobing Wang*. Harmine-Based Dual Inhibitors Targeting Histone Deacetylase (HDAC) and DNA as a Promising Strategy for Cancer Therapy. Bioorganic Chemistry (IF: 5.275), 2022, 120, 105604. DOI: 10.1016/j.bioorg.2022.105604

陆德华同学一篇JMC，一篇Bioorg Chem，热烈祝贺！

Dehua Lu, Lailiang Qu, Cheng Wang, Heng Luo, Shang Li, Fucheng Yin, Xingchen Liu, Xinye Chen, Zhongwen Luo, Ningjie Cui, Wan Peng, Limei Ji, Lingyi Kong*, and  Xiaobing Wang*. Harmine-Based Dual Inhibitors Targeting Histone Deacetylase (HDAC) and DNA as a Promising Strategy for Cancer Therapy. Bioorganic Chemistry (IF: 5.275), 2022, 120, 105604. DOI: 10.1016/j.bioorg.2022.105604